Abstract:The burden of chronic liver disease is globally increasing at an alarming rate. Chronic liver injury leads to liver inflammation and fibrosis (LF) as critical determinants of long-term outcomes such as cirrhosis, liver cancer, and mortality. LF is a wound-healing process characterized by excessive deposition of extracellular matrix (ECM) proteins due to the activation of hepatic stellate cells (HSCs). In the healthy liver, quiescent HSCs metabolize and store retinoids. Upon fibrogenic activation, quiescent HSCs transdifferentiate into myofibroblasts; lose their vitamin A; upregulate α-smooth muscle actin; and produce proinflammatory soluble mediators, collagens, and inhibitors of ECM degradation. Activated HSCs are the main effector cells during hepatic fibrogenesis. In addition, the accumulation and activation of profibrogenic macrophages in response to hepatocyte death play a critical role in the initiation of HSC activation and survival. The main source of myofibroblasts is resident HSCs. Activated HSCs migrate to the site of active fibrogenesis to initiate the formation of a fibrous scar. Single-cell technologies revealed that quiescent HSCs are highly homogenous, while activated HSCs/myofibroblasts are much more heterogeneous. The complex process of inflammation results from the response of various hepatic cells to hepatocellular death and inflammatory signals related to intrahepatic injury pathways or extrahepatic mediators. Inflammatory processes modulate fibrogenesis by activating HSCs and, in turn, drive immune mechanisms via cytokines and chemokines. Increasing evidence also suggests that cellular stress responses contribute to fibrogenesis. Recent data demonstrated that LF can revert even at advanced stages of cirrhosis if the underlying cause is eliminated, which inhibits the inflammatory and profibrogenic cells. However, despite numerous clinical studies on plausible drug candidates, an approved antifibrotic therapy still remains elusive. This state-of-the-art review presents cellular and molecular mechanisms involved in hepatic fibrogenesis and its resolution, as well as comprehensively discusses the drivers linking liver injury to chronic liver inflammation and LF.

Hepatic stellate cell-expressed endosialin balances fibrogenesis and hepatocyte proliferation during liver damage

Hepatic stellate cells limit hepatocellular carcinoma progression through the orphan receptor endosialin

CD248/endosialin critically regulates hepatic stellate cell proliferation during chronic liver injury via a PDGF-regulated mechanism

Regulatory Long Non-Coding RNAs of Hepatic Stellate Cells in Liver Fibrosis (Review)

Metabolic Hallmarks of Hepatic Stellate Cells in Liver Fibrosis

Hepatic Stellate Cell: A Double-Edged Sword in the Liver

Heterogeneity of Hepatic Stellate Cells in Fibrogenesis of the Liver: Insights from Single-Cell Transcriptomic Analysis in Liver Injury

The Endothelium as a Driver of Liver Fibrosis and Regeneration

Hepatic stellate cells as key target in liver fibrosis

Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets

Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis

Targeting Endothelial Erk1/2-Akt Axis As a Regeneration Strategy to Bypass Fibrosis During Chronic Liver Injury in Mice.

Hepatic stellate cells: a target for the treatment of liver fibrosis

Hepatic Stellate Cell Behavior during Resolution of Liver Injury

From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells

The HLF/IL-6/STAT3 Feedforward Circuit Drives Hepatic Stellate Cell Activation to Promote Liver Fibrosis

The Hepatocyte-Specifically Expressed Lnc-Hser Alleviates Hepatic Fibrosis by Inhibiting Hepatocyte Apoptosis and Epithelial-Mesenchymal Transition.

Hepatocytes in liver injury: Victim, bystander, or accomplice in progressive fibrosis?

Autophagy and Exosomes: Cross-Regulated Pathways Playing Major Roles in Hepatic Stellate Cells Activation and Liver Fibrosis